Navigation Links
Anticlotting drug found to be safe in sickle cell patients
Date:10/11/2007

CHAPEL HILL - An intravenous blood thinner widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.

We have tested a potentially promising drug in sickle cell patients, and the drug appears to be well tolerated. This gives us the impetus to go ahead with further studies of eptifibatide in these patients, said Dr. Leslie V. Parise, department chair and professor of biochemistry and biophysics at the UNC-Chapel Hill School of Medicine.

The hallmark of sickle cell disease is malformed red blood cells that can cause sudden painful episodes when they block small blood vessels. However, sickle cell patients are also at increased risk of developing multiple other complications, including strokes, lung complications and pulmonary hypertension.

The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called crises, is unpredictable and may occur often in some patients.

The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes.

Parise emphasized the need for further study. We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time, she said.

The results of the study were published online (Oct. 6) in the British Journal of Haematology.

The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode, said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill.

In the current study, blood tests showed that while the patients liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting.

Previous studies conducted by Sheritha Lee a graduate student in Parises lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatides known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients.


'/>"/>

Contact: Les Lang
LLANG@MED.UNC.EDU
919-843-9687
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Distraction therapy found very effective in postoperative patients
2. Genetic differences found between Male and Female brains
3. Breastfeeding not found to have an impact on weight of the child.
4. Common Cold Found to Fight Cancer Cells
5. Mentally Demanding Jobs Found To Reduce The Risk Of Alzheimer’
6. Caffeine Found To Worsen Diabetes
7. Drug Found To Bring Relief For Individuals With Early Parkinson’
8. Environmental Factors Found To Have An Impact On The Sex of A Child
9. New molecule to treat brain disorders found
10. Higher Rates Of Diabetes Found Among The Poor
11. Antioxidants found in chocolates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: